Clinical Trial Update: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of rituximab and cyclophosphamide in patients with high-risk, refractory, or relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituxan (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2015-06-11